---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-25-000084"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T01:01:48.695296+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio stockholders approve 2025 Equity Incentive Plan, re-elect directors

## Summary
- 2025 Equity Incentive Plan approved; reserves 46,088,027 new shares plus up to 32,359,674 from expired/forfeited 2015 Plan awards.
- All eight director nominees re-elected at June 18, 2025 annual meeting; 89% of shares represented.
- Deloitte & Touche ratified as independent auditor for fiscal 2025 with 99.5% votes in favor.
- Plan replaces 2015 Plan; no further awards under prior plan, but existing grants continue.

## SEC filing metadata
- accession: 0001326110-25-000084
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000084/0001326110-25-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000084/ibrx-20250618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-25-000084
- JSON: https://secwatch.observer/filing/0001326110-25-000084.json
- Plain text: https://secwatch.observer/filing/0001326110-25-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.